HomeCompareUMRRF vs MRK

UMRRF vs MRK: Dividend Comparison 2026

UMRRF yields 73.40% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 UMRRF wins by $2843631888565.66M in total portfolio value
10 years
UMRRF
UMRRF
● Live price
73.40%
Share price
$0.19
Annual div
$0.14
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2843631888565.71M
Annual income
$2,836,209,087,779,137,000.00
Full UMRRF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — UMRRF vs MRK

📍 UMRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUMRRFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, UMRRF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
UMRRF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

UMRRF
Annual income on $10K today (after 15% tax)
$6,239.18/yr
After 10yr DRIP, annual income (after tax)
$2,410,777,724,612,266,500.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, UMRRF beats the other by $2,410,777,724,612,258,300.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of UMRRF + MRK for your $10,000?

UMRRF: 50%MRK: 50%
100% MRK50/50100% UMRRF
Portfolio after 10yr
$1421815944282.89M
Annual income
$1,418,104,543,889,573,400.00/yr
Blended yield
99.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

UMRRF
No analyst data
Altman Z
-1.4
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

UMRRF buys
0
MRK buys
0
No recent congressional trades found for UMRRF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUMRRFMRK
Forward yield73.40%2.76%
Annual dividend / share$0.14$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$2843631888565.71M$56.8K
Annual income after 10y$2,836,209,087,779,137,000.00$9,798.13
Total dividends collected$2843144056464.38M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: UMRRF vs MRK ($10,000, DRIP)

YearUMRRF PortfolioUMRRF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$25,380$14,680.41$11,206$366.19+$14.2KUMRRF
2$96,801$69,643.91$12,650$502.35+$84.2KUMRRF
3$600,067$496,489.78$14,407$694.19+$585.7KUMRRF
4$6,394,835$5,752,763.36$16,585$967.82+$6.38MUMRRF
5$121,433,988$114,591,514.54$19,342$1,363.89+$121.41MUMRRF
6$4,197,266,167$4,067,331,799.59$22,913$1,947.19+$4197.24MUMRRF
7$267,264,882,042$262,773,807,243.66$27,662$2,823.89+$267264.85MUMRRF
8$31,561,431,416,403$31,275,457,992,618.20$34,159$4,173.35+$31561431.38MUMRRF
9$6,937,196,996,801,481$6,903,426,265,185,930.00$43,337$6,308.80+$6937196996.76MUMRRF
10$2,843,631,888,565,714,400$2,836,209,087,779,137,000.00$56,776$9,798.13+$2843631888565.66MUMRRF

UMRRF vs MRK: Complete Analysis 2026

UMRRFStock

US Masters Residential Property Fund (Fund) was established in 2011 and is listed on the Australian Securities Exchange (URF.ASX). The Fund was established to give investors exposure to US residential property and is the largest Australian-listed property trust with a primary strategy of investing in freestanding and multi-tenant US residential property in the New York metropolitan area. The Fund is focused on seeking to achieve long-term returns through a combination of income from rental yields along with potential long-term capital growth. Since 2011, the Fund's portfolio has grown to 982 housing units across 551 freestanding properties, with a gross asset value of approximately $1.2 billion (as at 30 June 2020). The Fund conducts all its New York metropolitan area residential investment through its controlled entity US Masters Residential Property (USA) Fund, a Maryland Real Estate Investment Trust (US REIT). A dedicated team of highly-skilled professionals based in New York manages every aspect of the real estate investment process – from acquiring the properties and rehabilitating the assets, to leasing the homes and ongoing tenant management.

Full UMRRF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this UMRRF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

UMRRF vs SCHDUMRRF vs JEPIUMRRF vs OUMRRF vs KOUMRRF vs MAINUMRRF vs JNJUMRRF vs ABBVUMRRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.